Good summary ST, Other than the actual exciting prospect of nnz2256, the part which I thought was important was the way they designed the P2a trials to gauge efficacy; they have stated that ANY improvement on the various testing scales will be considered, giving us a very broad sweep of what otherwise might not be 'efficacy' in other drugs. TBI is an interesting target area, and I believe is a 'graveyard' for many drugs simply because the end result is more or less debateable... Take a cancer drug for example, their aim is to reduce, stop or destroy the cancer. That is pretty obvious to determine, it either works or it doesn’t. Since NEU's active target area is the most complex thing known to man we may in fact have an advantage in the 'grey area' in which efficacy is judged.
Now this might not turn out to be true, but IMHO I cannot see the main funders (US Army) pulling the plug if we rate some results in that trial... Failing some catastrophic collapse in US Military budget, if they find a drug (who they have already selected from around 100 others) actually HAS the effect (to whatever extent) they are after; one would imagine that they will make sure it is viable.
My 2c to this only, DYOR, many thanks to those who continually help the NEU thread.
P.S. I’ve got to know what those 3 drugs are ST!!
Best,
Sol *with Santa hat*
NEU Price at posting:
2.8¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)